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It has recently been shown (Desgranges et al., 1986)
that bromovinyluracil [BVU: (E)-5-(2-bromo-
vinyl)uracil] increases the antitumour effect of 5-
fluorouracil (5-FU) in DBA/2 mice inoculated with
P388 leukaemia cells, most likely by inhibiting
5-FU degradation in vivo. The inhibitory effect is
apparently due to the effect of BVU on dihydro-
thymine dehydrogenase, the rate-limiting enzyme
in the catabolism of pyrimidines. It has also been
reported that bromovinyldeoxyuridine [BVDU;
(E)-5-(2-bromovinyl)-2'-deoxyuridine] is rapidly
converted to BVU in vivo (Desgranges et al., 1984)
and induces the same synergistic antitumour effect
with 5-FU as observed upon injection of BVU
(Desgranges et al., 1986). BVDU itself is an anti-
viral compound with great promise for the
treatment of herpes simplex virus (type 1) and
varicella-zoster virus infections (de Clercq &
Walker, 1984).
We have shown (Ben-Efraim et al., 1986) that
treatment of MOPC-315 plasmacytoma tumour cells
for 1 h with a minimal dose of 0.Ipg 5-FU/107
cells caused marked reduction in incorporation of
(methyl)3H thymidine (up to 68% of the degree of
thymidine incorporation in control untreated cells).
No attempts were made to determine the effect of
extending the length of the 5-FU treatment interval
on tumour cells. In view of results obtained with
other tumour lines (Drewinko & Yang, 1985), it
might be that extending the length of 5-FU
treatment of tumour cells will result in more
marked inhibition of thymidine incorporation and
possibly in reduction of the minimal effective dose
of 5-FU.
The data indicating tumouricidal effect in vitro of
5-FU on MOPC-315 tumour cells prompted us to
evaluate the effect of 5-FU therapy in mice bearing
MOPC-315 plasmacytoma tumours. We found
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(Ben-Efraim et al., 1986) that a single injection of
5-FU at 200mgkg-1 in BALB/c mice bearing large
MOPC-315 plasmacytomas induced transient
regression of the tumours. At doses <200mgkg-1,
5-FU was without effect (Ben-Efraim et al., 1986). In
view of the inhibitory effect of BVDU (via BVU) on
the degradation of 5-FU (Desgranges et al., 1986), it
appeared of interest to determine whether low doses
of 5-FU which did not affect development of estab-
lished MQPC-315 plasmacytoma tumours alone,
could be more effective when administered in
combination with BVDU.
The MOPC-315 myeloma cell line employed in
this study grows preferentially in the mouse
BALB/c strain and is characterized by its ability to
secrete anti-TNP trinitrophenyl) IgAA2 immuno-
globulin (Eisen et al., 1968). Subcutaneous
inoculation of 1 x 105 MOPC-315 tumour cells
invariably induces formation of local tumour which
reach a size of 15.0 mm on the 11th day after
inoculation and death within 20 days. An in vitro
line of MOPC-315 tumour cells, adapted to growth
in culture (Yaniv et al., 1978), was maintained in
RPMI 1640 medium (GIBCO, NY, USA), supple-
mented with 100Uml-1 penicillin, 100 igml-1
streptomycin, 2mmolml-1 L-glutamine, and 10%
foetal calf serum. The MOPC-315 cell line was used
for evaluating the in vitro effects of BVDU and
5-FU on (methyl)3H thymidine (Nuclear Research
Centre, Negev, Israel; 1.0pCi/50Ml/culture) incor-
poration in tumour cells. BVDU was synthesized
at the Rega Institute for Medical Research Leuven,
Belgium following a described procedure (Jones
et al., 1979). 5-FU was kindly donated by Abic,
Ramat-Gan, Israel. The effect of BVDU and 5-FU
on MOPC-315 tumour cells in vitro were monitored
in incubating 1 x 107 cells with varying compound
concentrations for 1 h at 37°C, washing the cells
with serum-free medium and further incubating the
cell cultures as described (Bocian et al., 1984). For
the experiments in vivo, groups of ten BALB/c mice
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(8-12 weeks old) were inoculated s.c. with 1 x 105
viable MOPC-315 tumour cells. BVDU (200 jmol -
69.5mgkg-1) was injected i.p. in a volume of
0.5ml on the 11th day after tumour cell inocula-
tion, followed 1 h later by a single i.p. injection of
varying doses of 5-FU in 0.5ml. Untreated inocu-
lated mice and mice treated with either BVDU or
5-FU alone served as controls. The mice were
observed for 60 days for tumour development and
death.
The significance of differences between groups
treated with 5-FU alone and corresponding groups
treated with 5-FU plus BVDU was calculated by
the double tailed Mann-Whitney U test. The rate of
tumour development in various groups as indicated
by measurements of tumour sizes was compared till
the 19th day after inoculation. Until this day, all of
the inoculated mice were still alive in the compared
groups. Differences were considered significant
when P<0.05. The therapeutic index (TI) was
calculated as ratio of maximum tolerated dose
(MLD) to minimumeffective dose (MED). According
to our previously reported data (Ben-Efraim et al.,
1986) the MLD for 5-FU was 250mgkg-1 body
weight. The MED was taken as the lowest quantity
of 5-FU which induced significant transient re-
gression of large MOPC-315 tumours. Injection
of 5-FU, 100mgkg- 1 body wt plus BVDU
(69.5mgkg-1) in normal, noninoculated mice did
not affect the survival of animals and did not cause
appreciable loss of weight.
Exposure of MOPC-315 tumour cells in vitro to
different concentrations of BVDU (0.5 to
100Mg I10 cells) for h did not affect the rate of
thymidine incorporation into the tumour cells. In
keeping with previous results (Ben-Efraim et al.,
1986), treatment of MOPC-315 tumour cells with
5-FU markedly reduced the extent of thymidine
incorporation into the cells (Table I). Treatment
with BVDU alone (69.5 mgkg-1) or 5-FU alone
(12.5 to I00mgkg-1), did not affect the growth of
MOPC-315 tumour in vivo. If however, 5-FU
treatment was combined with BVDU treatment,
5-FU at doses ranging from 25 to 100mgkg-1,
caused a transient regression of MOPC-315
tumours and prolongation of survival time. The
kinetics of tumour development are presented in
Figures la, b and the rates of survival are shown in
Figures 2a, b. The therapeutic index (TI) was 2.5
for mice treated with 5-FU alone (250 mgkg- 1
MLD/100mgkg-1 MED) and 20.0 for mice treated
with a combination of 5-FU plus BVDU
(250mgkg-1 MLD/12.5mgkg- 1 MED).
Our findings indicate that BVDU has a poten-
tiating effect on the antitumour activity of 5-FU
in mice bearing large progressively growing MOPC-
315 tumours. These results are in agreement with
previously reported data (Desgranges et al., 1986)
Table I Effect of bromovinyldeoxyuridine (BVDU) and
5-fluorouracil (5-FU) on [methyl-H]thymidine
incorporation in MOPC-315 tumour cells in vitro.
[methyl-3H]thymidine
Treatmenta incorporationb
Compound /ig 10-' cells cpm+s.e. % ofcontrol
None 220,064+ 12,994
BVDU 0.5 291,128±5,030 132.2
5.0 219,924+3,126 99.9
15.0 217,218 +3,604 98.7
30.0 196,562+3,394 89.3
100.0 229,560+5,943 104.3
None 178,044+3,933
5-FU 3.0 79,837+ 15,360 44.7
10.0 42,312+5,596 23.7
30.0 57,829+3,936 32.4
aMOPC-315 tumour cells were incubated for 1 h with the
compound at 37°C and washed 3 times before culturing;
tumour cells incubated in medium alone were used as
controls; bTumour cells were cultured for 72h; [methyl-
3H]thymidine (l uCi/culture) was added for the last 6h of
incubation; 2 x 104 tumour cells/culture; cpm represent
means (±s.e.) for 16 parallel samples; % of thymidine
incorporation is expressed as function ofthe corresponding
control.
on the synergistic antitumour activity of BVDU
and 5-FU in DBA/2 mice inoculated with P388
leukaemia cells. BVDU alone does not affect
MOPC-315 tumour cells either in vitro or in vivo.
Since BVDU is readily converted in vivo to BVU
(Desgranges et al., 1984) and since BVU is capable
of inhibiting the degradation of 5-FU in vivo
(Desgranges et al., 1986), one may postulate that
the increased antitumour activity of combined
BVDU and 5-FU therapy in the MOPC-315 model
is due to a decrease in the degradation of 5-FU,
and hence greater bio-availability of the compound.
Under the experimental conditions used (i.e.
single doses of both BVDU and 5-FU), only a
transient regression of MOPC-315 tumours was
observed. It would seem imperative to examine
whether a more intensive treatment regimen, i.e.
higher doses of BVDU and/or repeated
administrations of BVDU and 5-FU, may yield a
more definitive prolonged or even definitive
regression of MOPC-315 tumours. In any case, the
combination of 5-FU and BVDU is an interesting
lead that should be further pursued as a therapeutic
modality in the treatment of cancer. Improvement
in effectiveness of 5-FU therapy may be of
importance in view of the doubts expressed
(Drewinko & Yang, 1985) on the efficacy of
therapy with this drug alone.BVDU EFFECT IN 5-FU THERAPY 849
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Figure 1 (a) Effect of treatment with bromovinyldeoxyuridine (BVDU) and 5-fluorouracil (5-FU) on the
development of MOPC-315 tumours.
1 (----) inoculated, untreated mice.
2 (......) inoculated, 5-FU 100 (mgkg-1).
3 (- - - -) inoculated, 5-FU 100 (mgkg-1)+BVDU 69.5 (mgkg 1).
4 (-----) inoculated, 5-FU 50 (mgkg-1).
5 ( --) inoculated, 5-FU 50 (mgkg-1)+BVDU 69.5 (mgkg 1).
6 ( ) inoculated, BVDU 69.5 (mgkg-1).
Significant differences (P<0.05) were found between groups 4 and 5 on days 13-19 after inoculation.
(b) Effect of treatment with bromovinyldeoxyuridine (BVDU) and 5-fluorouracil (5-FU) on the develop-
ment of MOPC-315 tumours.
1 (----) inoculated, untreated mice.
2 (.....) inoculated, 5-FU 25 (mgkg 1).
3 (-- - -) inoculated, 5-FU 25 (mgkg-1)+BVDU 69.5 (mgkg 1).
4 (------) inoculated, 5-FU 12.5 (mgkg-1).
5 (---) inoculated, 5-FU 12.5 (mgkg-1)+BVDU 69.5 (mgkg 1).
Significant differences (P<0.05) were found between groups: 2 vs. 3: days 13-19 after inoculation; 4 vs. 5:
days 13-16 after inoculation.
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Figure 2 (a) Survival times after inoculation with MOPC-315 tumour cells and treatment with bromovinyl-
deoxyuridine (BVDU) and 5-fluorouracil (5-FU).
1 (----) inoculated, untreated mice.
2 (. ) inoculated, 5-FU 100 (mgkg-).
3 (- - -) inoculated, 5-FU 100 (mgkg-1)+BVDU 69.5 (mgkg1).
4 (------) inoculated, 5-FU 50 (mgkg-1).
5 (---) inoculated, 5-FU 50 (mgkg-1)+BVDU 69.5 (mgkg1).
6 (-) inoculated, BVDU 69.5 (mgkg-1).
(b) Survival times after inoculation with MOPC-315 tumour cells and treatment with bromovinyldeoxy-
uridine (BVDU) and 5-fluorouracil (5-FU).
1 (- --) inoculated, untreated mice.
2 C. ) inoculated, 5-FU 25 (mgkg -).
3 (-- - -) inoculated, 5-FU 25 (mgkg-1)+BVDU 69.5 (mgkg1).
4 (- ) inoculated, 5-FU 12.5 (mgkg-').
5 (---) inoculated, 5-FU 12.5 (mgkg-1)+BVDU 69.5 (mgkg1).BVDU EFFECT IN 5-FU THERAPY 851
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